Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exact Sciences Corp. (EXAS)
NASDAQ:EXAS
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.33Last Year’s EPS
-0.6Same Quarter Last Year
Strong Buy
Based on 15 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 19, 2025
|% Change Since: 0.00%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance with significant revenue and EBITDA growth, especially in the Screening segment. The company highlighted major achievements like FDA approval for Cologuard Plus and strong international expansion in Precision Oncology. However, the call also addressed challenges such as a substantial non-cash impairment charge related to the Thrive acquisition and modest growth in Precision Oncology. Overall, the positive aspects of revenue growth, new product launches, and strategic advancements outweigh the lowlights, indicating a positive sentiment.Company Guidance
During the Exact Sciences Fourth Quarter 2024 Earnings Call, the company provided guidance for 2025, projecting total revenue between $680 million and $695 million for Q1, and between $3.025 billion and $3.085 billion for the full year. Screening revenue is expected to be between $520 million and $530 million for Q1, and $2.35 billion to $2.39 billion for the year. Precision Oncology revenue is forecasted to be between $160 million and $165 million for Q1, and $675 million to $695 million for the full year. Adjusted EBITDA for 2025 is expected to be between $410 million and $440 million, with an anticipated 220 basis point expansion in adjusted EBITDA margin. The company also highlighted key growth drivers including a 13% increase in Screening revenue, supported by the launch of Cologuard Plus, and a 5% growth in Precision Oncology, with strong international performance of Oncotype DX.Strong Revenue Growth
Fourth quarter revenue grew 10% with a 14% increase in Screening revenue to $553 million. Precision oncology revenue increased slightly to $161 million.
Significant EBITDA Improvement
Adjusted EBITDA increased 52% to $75 million. Adjusted EBITDA margin expanded nearly 300 basis points.
FDA Approval and Medicare Pricing for Cologuard Plus
Secured FDA approval and Medicare pricing for Cologuard Plus, a next-generation colon cancer screening test, with a Medicare price of $592.
Positive Outlook for 2025
Guidance for 2025 anticipates total revenue between $3.025 billion and $3.085 billion, with 11% total revenue growth, including 13% in Screening.
Recognition as a Great Place to Work
Exact Sciences was recognized as a great place to work for the sixth consecutive year.
Expansion in Precision Oncology
Strong double-digit growth internationally in Precision Oncology, leveraging the Oncotype DX brand.
---
EXAS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
EXAS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 19, 2025 | $50.48 | ― | ― |
| Nov 05, 2024 | $71.51 | $54.72 | -23.48% |
| Jul 31, 2024 | $45.68 | $57.91 | +26.77% |
| May 08, 2024 | $59.48 | $54.15 | -8.96% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Exact Sciences Corp. (EXAS) report earnings?
Exact Sciences Corp. (EXAS) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Exact Sciences Corp. (EXAS) earnings time?
Exact Sciences Corp. (EXAS) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EXAS EPS forecast?
EXAS EPS forecast for the fiscal quarter 2025 (Q1) is -0.33.
---